Related Jobs
-
Clinical Trial Assistant
Job Type: Permanent
Salary: € 12000.00 per annum
Location: Romania -
Clinical Research Associate II
Job Type: Permanent
Salary: Salary on application
Location: Romania
Step forward for cancer gene therapy
22 Nov 2006
Clinical Research
Preclinical work on gene therapy in cancer cells has shown signs of significant treatment potential, according to researchers at the University of Texas.
Scientists from the university's M. D. Anderson Cancer Centre found that the NPRL2 tumour suppressor gene inhibited 90 per cent of tumour growth in lung cancer cells.
The novel treatment, developed by Introgen, bodes well for the introduction of clinical trials; it is envisaged the gene therapy may provide a treatment option for patients resistant to standard cisplatin chemotherapy.
"The ability to use a simple biomarker assay for NPRL2 to identify patients who would not derive benefit from cisplatin represents an important advance and underscores the significance of NPRL2 in lung cancer," said vice president of research at Introgen, Dr Sunil Chada.
"Development of NPRL2 gene drugs using systemic nanoparticle delivery may help patients whose tumours are resistant to cisplatin by re-sensitising tumours to this commonly used therapy."
Introgen has a global licence to develop therapies based on ten potential anti-cancer genes, including NPRL2 and FUS1.
© Adfero Ltd
